Trade names normally aren’t established and trademarked until after FDA preliminary approval of a drug.  Looks like our friends at Onyx are pretty confident that the FDA will step-up and quickly approve carfilzomib for relapsed/refractory myeloma patients.

I need to put details about my own story–and RVD “light,” on hold for a day to discuss some breaking news with you.

When perifosine failed to extend overall survival (OS) in patients with metastasized colorectal cancer recently in a Stage 3 trial, company officials and financial analysts speculated that plans to start a stage 3 multiple myeloma theory might be scrapped:

This story is very close to my heart.  Not only is Don Wright a close friend, but former NFL football player, Elijah Alexander, and I became friends before he died a a year or so ago.

I’ll bet that no one else noticed this feature on Sokolove Law, LLC’s website?

While we were busy being inspired–and reading nutritional tips to help us control our myeloma–there was a lot going on with the new myeloma therapies and the FDA.

What about sage and basil, the next recommendations?

DANNY’S BACK!  After a long trip to Europe and a protracted battle with a viral infection, our good friend and nutritional myeloma guru, Danny Parker, sent me so much great copy this week–I’m going to run it in two installments:

Patients and caregivers were “all abuzz” last week over the new ImMucin anti-cancer vaccine.  I even wrote two posts about it:

Here is some follow-up on a more well tested anti-myeloma antibody, Elotuzumab–the kind of therapy you will find featured in my new myeloma therapies book.

Wow!  This continuing ed course for medical oncologists and hematologists is really interesting!

More odds and ends to share…

Happy Saturday!  I thought this might be a good day to group together and share several different multiple myeloma-related odds and ends…

I just noticed that the first link was broken from yesterday’s post that contained links to important Myeloma Beacon columns–and several other resources about peripheral neuropathy (PN).   It is fixed if you would like more background information and helpful suggestions from past years.

Things don’t always go as well as we expect, right?

I attended a Florida Educational Advocacy Group event last evening at Moffitt Cancer Center in Tampa.  The topic:  New Treatment Options for Multiple Myeloma.

Yesterday I re-visited the topic of a new anti-myeloma therapy Mayo Clinic researchers are investigating.

Although this Cancer Network article never mentions multiple myeloma specifically, it could be all about myeloma.

Yesterday’s post provided a link to an article which questioned if physicians are “in the pocket” of pharmaceutical companies which produce opioid pain meds.

This is the type of thing that I usually post on MyelomaNews.com.